Category: BioTech

Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Diageo Price Talk Will Tighten, Best Ideas’ SABMiller Bonds Comparatively Cheaper

Diageo is the world’s largest spirits maker, and the strength of its portfolio is unmatched. With eight of the world’s top 25 brands and unrivaled global distribution scale, the firm generates robust free cash flows and has a wide economic moat, in our view. With its strong brand portfolio and unmatched distribution scale, the firm is able to leverage its strength to gain shelf space … Continue reading Diageo Price Talk Will Tighten, Best Ideas’ SABMiller Bonds Comparatively Cheaper

John MeadyLeave a comment
BioTech, Finance

Biotech Stocks to Watch: AbbVie, Bind Therapeutics & MannKind

In the news on the Biotech Segment, we take a close look at three upcoming Biotech stocks in AbbVie, Bind Therapeutics & MannKind. Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders that a buyout is in their best interest. Per sources familiar with the dealings, AbbVie’s CEO Richard Gonzalez traveled to London recently to hold discreet … Continue reading Biotech Stocks to Watch: AbbVie, Bind Therapeutics & MannKind

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

ConocoPhillips Makes Progress on Portfolio Transition

ConocoPhillips COP reported first-quarter earnings that indicated its shift to higher-margin assets continues at a healthy pace. Specifically, production from the Eagle Ford, Bakken and Permian was 182 mboe/d in the first quarter, a 42% increase over last year. The increase in production for these plays along with increased oil sands production in Canada shifted ConocoPhillips’ North American oil exposure (excluding Alaska) to 51% from … Continue reading ConocoPhillips Makes Progress on Portfolio Transition

John MeadyLeave a comment
Biotech stock market news
BioTech, Finance

Biotech Stocks Roundup: Amgen & Alexion

In the news on the Biotech Segment, stocks remained majorly volatile. With the news in the biotech market segment being dominated by the likes of Abbvie (ABBV), who is trying to acquire Ireland-based Shire (SHPG), we take a look at the other stocks which were in the news and are looking positive: Amgen & Alexion. Let’s take a closer look at both of them. Alexion … Continue reading Biotech Stocks Roundup: Amgen & Alexion

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

RBS` recovery is on track, but its exposure to Ireland will continue to mean heavy loan losses.

Morningstar’s credit rating of BBB+ for Royal Bank of Scotland reflects the bank’s large balance of nonperforming loans but is bolstered by the recent improvements in the bank’s operating performance. Through acquisitions, Royal Bank of Scotland has become a global bank, with operations in 50 countries. RBS is primarily a business bank and is dominated by its global banking and markets division, which has historically … Continue reading RBS` recovery is on track, but its exposure to Ireland will continue to mean heavy loan losses.

John MeadyLeave a comment
Biotech stock market news
BioTech, Finance

Active Biotech Stocks: Medivation & Vivus

Here we take a close look at two upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. Xtandi could very well be a game-changer for Medivation. Vivus posted extremely postive results off late but there are reasons to worry if you are an investor of Vivus. Let’s take a closer look at the three stocks. Medivation gained 8.5% even though … Continue reading Active Biotech Stocks: Medivation & Vivus

Richard Atkins